Connect with us

Hi, what are you looking for?

Stock

Humana tops estimates on strength in Medicare and primary care

By Sriparna Roy and Amina Niasse

(Reuters) -Humana beat Wall Street estimates for third-quarter profit on Wednesday as it added more members than expected in its government-backed Medicare Advantage insurance business for older adults, and saw strength in its primary care segment CenterWell.

The health insurer, a top provider of Medicare Advantage plans, said it expects “at least” $16 per share in adjusted profit for the full year, compared with its previous forecast of “approximately” $16 per share.

Shares of the Louisville, Kentucky-based company rose more than 4% in morning trade.

For 2025, Humana (NYSE:HUM) said it expects adjusted profit to be at least in line with final 2024 results. Analysts expect a 2025 profit of $19.77 per share, according to data compiled by LSEG.

“We want to be appropriately prudent and make sure that we’re doing the right things to establish targets, hit those targets, build credibility over time,” Jim Rechtin, CEO of Humana said in a conference call. “We are trying to establish the best way to navigate through the next 24 months.”

Insurers providing Medicare Advantage plans have faced challenges recently due to rising healthcare expenses among older adults. These challenges were compounded by recent government payment rates, making it difficult for insurers to cover the higher medical costs without impacting profits.

Concerns about 2024 have been alleviated, but expectations for 2025 suggest a flat year with minimal growth, which is “a much lower bar than expected,” said Baird analyst Michael Ha.

PERFORMANCE RATINGS

Humana shares, among the sector’s most hard hit, have fallen nearly 44% so far this year, after the company withdrew its 2025 forecast previously, citing disappointing government Medicare reimbursement rates.

Humana launched a suit in October against the U.S. Department of Health and Human Services over the Medicare agency’s calculation of its performance ratings.

A downgrade in the quality rating for a widely used Medicare insurance plan, which accounts for nearly half of its Medicare Advantage (MA) memberships, could potentially weigh on the insurer’s revenue and bonus payments in 2026.

For 2027, the company expects to return its Medicare Advantage margins to at least 3%, but that target is at risk of erosion following drops in Humana’s quality rating, Rechtin said.

For the full year, Humana anticipates individual net membership growth in its MA business of about 265,000, up from its previous estimate of about 225,000.

Humana’s appeal of its quality rating will not have a significant impact on the company’s future investments, Rechtin said.

The company also warned of higher than expected inpatient admissions – hospitalizations that require an overnight stay.

Humana Chief Financial Officer Susan Diamond said the company saw an initial uptick in inpatient claim appeals following the implementation in 2023 of a CMS rule that defines an inpatient facility as one where patients stay two nights.

Inpatient claim appeals have leveled off since and remain in line with first-quarter figures, Diamond said.

Humana reported a third-quarter medical cost ratio – the percentage of premiums spent on medical care – of 89.9%, in line with analyst expectations.

Revenue at its CenterWell segment rose 8% to $5.04 billion for the quarter.

Humana also posted an adjusted profit of $4.16 per share, beating estimates of $3.40.

This post appeared first on investing.com






    You May Also Like

    Editor's Pick

    Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

    Latest News

    A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

    Economy

    A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

    Investing

    Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

    Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 balanceandcharge.com